Table 2.
Quarterly age-standardized chronic liver disease-related mortality and quarterly percentage change (QPC) among US adults (≥ 20 Years) with diabetes listed on the death certificate based on the sex in 2017–2020.
| Age-standardized rate (per 100,000 individuals) |
Average QPC (95% CI) | Trend segment 1 |
Trend segment 2 |
|||||
|---|---|---|---|---|---|---|---|---|
| 2017 Q1 | 2019Q4 | 2020 Q4 | 2017–2020 | Year | QPC (95% CI) | Year | QPC (95% CI) | |
| Men | ||||||||
| Chronic liver disease | 0.61 | 0.60 | 0.78 | 2.3 (1.3, 3.3)* | 2017 Q1–2019 Q4 | 0.4 (−0.4, 1.1) | 2019 Q4–2020 Q4 | 7.7 (3.9, 11.5)* |
| Cirrhosis | 0.42 | 0.43 | 0.57 | 2.6 (1.7, 3.5)* | 2017 Q1–2019 Q4 | 0.7 (0.0, 1.4)* | 2019 Q4–2020 Q4 | 7.9 (4.6, 11.4)* |
| Hepatocellular carcinoma | 0.08 | 0.08 | 0.08 | 0.9 (0.2, 1.6)* | ||||
| Alcohol-related liver disease | 0.11 | 0.13 | 0.18 | 3.7 (2.2, 5.2)* | 2017 Q1–2019 Q4 | 2.2 (1.0, 3.3)* | 2019 Q4–2020 Q4 | 8.0 (2.4, 13.8)* |
| Hepatitis C | 0.19 | 0.13 | 0.15 | −0.6 (−2.4, 1.3) | 2017 Q1–2019 Q3 | −2.9 (−4.6, −1.2)* | 2019 Q3–2020 Q4 | 4.3 (−0.8, 9.7) |
| Nonalcoholic fatty liver disease | 0.04 | 0.05 | 0.07 | 3.7 (2.7, 4.7)* | ||||
| Women | ||||||||
| Chronic liver disease | 0.35 | 0.35 | 0.51 | 2.6 (1.1, 4.1)* | 2017 Q1–2019 Q4 | 0.2 (−0.9, 1.3) | 2019 Q4–2020 Q4 | 9.5 (3.9, 15.4)* |
| Cirrhosis | 0.27 | 0.27 | 0.39 | 2.8 (1.4, 4.1)* | 2017 Q1–2019 Q4 | 0.4 (−0.6, 1.4) | 2019 Q4–2020 Q4 | 9.5 (4.4, 14.7)* |
| Hepatocellular carcinoma | 0.02 | 0.03 | 0.04 | 2.3 (0.8, 3.8)* | ||||
| Alcohol-related liver disease | 0.03 | 0.04 | 0.05 | 2.8 (1.5, 4.1)* | ||||
| Hepatitis C | 0.07 | 0.05 | 0.07 | −0.9 (−4.2, 2.6) | 2017 Q1–2019 Q3 | −4.0 (−7.2, −0.8)* | 2019 Q3–2020 Q4 | 5.8 (−3.9, 16.4) |
| Nonalcoholic fatty liver disease | 0.06 | 0.06 | 0.12 | 4.2 (1.4, 7.2)* | 2017 Q1–2019 Q4 | 1.7 (−0.5, 3.9) | 2019 Q4–2020 Q4 | 11.7 (0.9, 23.5)* |
Abbreviation: QPC, quarterly percentage change; Q, quarter; CI, confidence interval.
⁎
P<0.05.